Grade 3 or 4 adverse events that differed significantly between the two groups included nausea ( eight [ 7 % ] vs one [ < 1 % ] ) , vomiting ( 13 [ 11 % ] vs one [ < 1 % ] ) , musculoskeletal pain ( none vs ten [ 8 % ] ) , anaemia ( 39 [ 33 % ] vs six [ 5 % ] ) , and thrombocytopenia ( 38 [ 32 % ] vs three [ 3 % ] ) , for the cisplatin plus gemcitabine compared with the paclitaxel plus gemcitabine groups , respectively .